The impact of lipoxin A.sub.4 (LXA.sub.4) and aspirin-triggered-lipoxins
(ATL) was investigated in tumor necrosis factor (TNF.alpha.)-initiated
neutrophil (PMN) responses in vitro and in vivo using metabolically stable
LX analogs. At concentrations as low as 1-10 nM, the LXA.sub.4 and ATL
analogs each inhibited TNF.alpha.-stimulated superoxide anion generation
and IL-1.beta. release by human PMN.
